Alkermes Plc (ALKS)
Alkermes plc is a biopharmaceutical company focused on researching, developing, and commercializing medicines for unmet medical needs in the United States, Ireland, and other international markets. Its commercial portfolio includes products for opioid dependence, alcohol dependence, schizophrenia, and bipolar I disorder, alongside a pipeline of clinical and preclinical candidates in neurological disorders. Marketed products include ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ. The company also licenses its proprietary technology platforms to third parties to support product development, commercialization, and manufacturing. Alkermes maintains collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc., and Janssen Pharmaceutica International. Founded in 1987, the company is headquartered in Dublin, Ireland, and its common stock trades on NASDAQ under the symbol ALKS.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ALKS
|
$49.43
|
-5.1% Downside
|
Fair
|
$52.65
|
1.1% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
July 28, 2026
|
56.9x
|
5.0x
|
5.6x
|
8.62 B
|
9.754 B
|
15.5%
|
92.4%
|
6.1
|
—
|
145.2%
|
